WO2021126344A3 - Compositions and methods comprising engineered bacteriophage - Google Patents

Compositions and methods comprising engineered bacteriophage Download PDF

Info

Publication number
WO2021126344A3
WO2021126344A3 PCT/US2020/053933 US2020053933W WO2021126344A3 WO 2021126344 A3 WO2021126344 A3 WO 2021126344A3 US 2020053933 W US2020053933 W US 2020053933W WO 2021126344 A3 WO2021126344 A3 WO 2021126344A3
Authority
WO
WIPO (PCT)
Prior art keywords
engineered bacteriophage
bacteriophage
compositions
methods
bacterium
Prior art date
Application number
PCT/US2020/053933
Other languages
French (fr)
Other versions
WO2021126344A2 (en
Inventor
Bryan Boen HSU
Isaac Nathan PLANT
Jeffrey Charles Way
Pamela A. Silver
Original Assignee
President And Fellows Of Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by President And Fellows Of Harvard College filed Critical President And Fellows Of Harvard College
Publication of WO2021126344A2 publication Critical patent/WO2021126344A2/en
Publication of WO2021126344A3 publication Critical patent/WO2021126344A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10311—Siphoviridae
    • C12N2795/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The technology described herein is directed to compositions and methods comprising engineered bacteriophage. In one aspect, described herein is an engineered bacteriophage comprising at least one nucleic acid encoding an inhibitor of a virulence factor encoded by a bacterium; and an immunity region from a second bacteriophage; wherein the engineered bacteriophage is lysogenic and infects the bacterium without killing the bacterium. In one aspect, described herein is a method of treating a bacterial infection comprising administering an engineered bacteriophage. In one aspect described herein is a method of inhibiting bacterial growth or activity on a surface comprising contacting a surface with an engineered bacteriophage.
PCT/US2020/053933 2019-10-03 2020-10-02 Compositions and methods comprising engineered bacteriophage WO2021126344A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962909988P 2019-10-03 2019-10-03
US62/909,988 2019-10-03

Publications (2)

Publication Number Publication Date
WO2021126344A2 WO2021126344A2 (en) 2021-06-24
WO2021126344A3 true WO2021126344A3 (en) 2021-07-29

Family

ID=76477969

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/053933 WO2021126344A2 (en) 2019-10-03 2020-10-02 Compositions and methods comprising engineered bacteriophage

Country Status (1)

Country Link
WO (1) WO2021126344A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023195008A1 (en) * 2022-04-05 2023-10-12 Mybiotics Pharma Ltd. Bacterial compositions and methods for growing bacteria on particles
WO2024052907A1 (en) * 2022-09-06 2024-03-14 Trobix Bio Ltd. Systems for production of transducing particles, methods, kits, compositions and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018141907A1 (en) * 2017-02-03 2018-08-09 Eligo Bioscience Optimized vector for delivery in microbial populations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018141907A1 (en) * 2017-02-03 2018-08-09 Eligo Bioscience Optimized vector for delivery in microbial populations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HSU, BS ET AL.: "Stable neutralization of virulent bacteria using temperate phage in the mammalian gut", BIORXIV, 7 October 2019 (2019-10-07), pages 1 - 22, XP055843427, DOI: 10.1101/794222 *
TYLER, JS ET AL.: "The Operator and Early Promoter Region of the Shiga Toxin Type 2-Encoding Bacteriophage 933W and Control of Toxin Expression", JOURNAL OF BACTERIOLOGY, vol. 186, no. 22, 15 November 2004 (2004-11-15), pages 7670 - 7679, XP055843425, DOI: 10.1128/JB.186.22.7670-7679.2004 *

Also Published As

Publication number Publication date
WO2021126344A2 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
WO2004027020A3 (en) Identification of a phage associated lytic enzyme to rapidly and specifically detect and kill bacillus anthracis
WO2021126344A3 (en) Compositions and methods comprising engineered bacteriophage
WO2005030186A3 (en) Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation
Massa et al. Survival of Escherichia coli O157: H7 in yoghurt during preparation and storage at 4 C
JP2019108378A5 (en)
WO2008042481A3 (en) A method for the detection and neutralization of bacteria
MXPA04005395A (en) Isolated phages and their use in food or pet food products.
WO2001051066A3 (en) Reduction in bacterial colonization by administering bacteriophage compositions
RU2014149348A (en) PREVENTION, DESTRUCTION AND PROCESSING OF BIOFILM BY BACTERIOPHAGE LYSINE
WO2006084210A3 (en) Hif modulating compounds and methods of use thereof
WO2004030624A3 (en) Compositions and methods for inhibiting pathogenic growth
WO2021195470A3 (en) Identification and use of compounds in the treatment or prevention of severe acute respiratory syndrome coronavirus 2
JP2013539776A5 (en)
WO2020201833A8 (en) Gepotidacin for use in the treatment of bacterial urinary tract infections
ATE259654T1 (en) PHARMACEUTICAL PREPARATIONS FOR THE CONTROL OR PROPHYLAXIS OF SURFACES INFECTED BY MICROORGANISMS
WO2019235782A8 (en) Novel streptococcus suis bacteriophage str-sup-2, and use thereof for inhibiting proliferation of streptococcus suis strains
JP2014503469A5 (en)
MX2023009332A (en) Compositions comprising exopolysaccharides and uses thereof.
EP1060745A3 (en) A composition and method for treating bacterial infection
WO2021231314A8 (en) Methods of treating covid-19 using tetracycline compounds
CA3156017A1 (en) Immunogenic compositions
CN102994456A (en) Artificially-synthesized S13 phage and applications thereof
Sinha et al. Bdellovibrio like organisms: the predatory assassin
MX2021011147A (en) Materials and methods for enhanced treatment and prevention of biofilms.
WO2020053275A3 (en) Animal feed composition comprising muramidase and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20903603

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20903603

Country of ref document: EP

Kind code of ref document: A2